drug-commercialization
(3)
TerSera Therapeutics
TerSera Therapeutics is a privately held biopharmaceutical company based in Deerfield, Illinois, focused on acquiring, developing, and commercializing specialty medicines in oncology, rare disease, and non-opioid pain. Launched in 2016 with backing from private equity firm GTCR, TerSera builds its portfolio through targeted acquisitions of approved and late-stage assets, including ZOLADEX, XERMELO, PRIALT, and VARUBI, with a stated mission of building 'the new cornerstones of care' for patients with limited treatment options.
Heidi Gillmore
Heidi Gillmore is a commercial leadership executive at TerSera Therapeutics, the Deerfield, Illinois specialty pharmaceutical company she helped build from its 2016 inception. Across roles spanning marketing, strategy, business development and running TerSera's US oncology business, she has helped turn a portfolio of 'one-and-only' therapeutics, including the prostate and breast cancer drug Zoladex, into a durable commercial enterprise. A University of Northern Iowa graduate with a University of Chicago credential, she sits on the board of the Illinois Biotechnology Innovation Organization and has spent her career taking specialty and orphan medicines from acquisition to market.
Steven Basta
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.